Jpmorgan Chase & CO Viridian Therapeutics, Inc.\De Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
152Shares Held
61.9MCall Options Held
133KPut Options Held
207K-
Black Rock Inc. New York, NY4.77MShares$109 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$89.6 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$88.7 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$76.4 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$75.6 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $911M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...